Nautilus Biotechnology vs Karius

Side-by-side comparison of AI visibility scores, market position, and capabilities

Karius leads in AI visibility (73 vs 34)
Nautilus Biotechnology logo

Nautilus Biotechnology

EmergingBiotechnology

Single-Molecule Proteomics

Nautilus Biotechnology is building a single-molecule proteomics platform to map and quantify the full human proteome at a scale and sensitivity previously impossible.

AI VisibilityBeta
Overall Score
D34
Category Rank
#175 of 198
AI Consensus
82%
Trend
stable
Per Platform
ChatGPT
36
Perplexity
30
Gemini
31

About

Nautilus Biotechnology is a proteomics company founded in 2016 and publicly listed on Nasdaq, developing a revolutionary platform for analyzing proteins at single-molecule resolution. While genomics has transformed medicine through DNA and RNA sequencing, the proteome is the actual functional layer of biology where drug targets, disease biomarkers, and therapeutic mechanisms operate. Nautilus is building a platform that can identify and quantify thousands of proteins simultaneously from tiny biological samples using a fluorescence-based single-molecule detection approach without requiring mass spectrometry. The platform promises to enable proteomics studies at a scale and depth comparable to what next-generation sequencing delivered to genomics, unlocking new insights into disease biology and drug development. Nautilus is in the instrument development phase and targets pharmaceutical research, clinical diagnostics, and academic biology. The company has raised over $250M and is building manufacturing capabilities for a planned commercial instrument launch that could define a new era in proteomics research.

Full profile
Karius logo

Karius

LeaderLife Sciences & BioTech

Genomic Infectious Disease Diagnostics

Karius raised $409M total including a $100M Series C in May 2024; its genomic blood test detects 1,000+ pathogens at 400+ U.S. hospitals; launched Karius Focus BAL for pneumonia in April 2025.

AI VisibilityBeta
Overall Score
B73
Category Rank
#12 of 198
AI Consensus
78%
Trend
stable
Per Platform
ChatGPT
69
Perplexity
70
Gemini
70

About

Karius is a Redwood City, CA-based life sciences company founded in 2014 that developed the Karius Test — a single blood draw that uses next-generation sequencing and AI to detect over 1,000 pathogens (bacteria, fungi, viruses, parasites) in seriously ill patients. The test is used when conventional cultures and targeted diagnostics fail, providing clinicians at transplant centers, children''s hospitals, and ICUs with a comprehensive pathogen report within 24 hours.

Full profile

AI Visibility Head-to-Head

34
Overall Score
73
#175
Category Rank
#12
82
AI Consensus
78
stable
Trend
stable
36
ChatGPT
69
30
Perplexity
70
31
Gemini
70
28
Claude
75
31
Grok
77

Key Details

Category
Single-Molecule Proteomics
Genomic Infectious Disease Diagnostics
Tier
Emerging
Leader
Entity Type
brand
brand

Capabilities & Ecosystem

Capabilities

Only Nautilus Biotechnology
Single-Molecule Proteomics

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.